

Informational Resources

PrEP Justice: Updates on the US v. Gilead Case and the Fight for Equitable PrEP Access

Webinar date: Wednesday, July 17, 2024

The Choice Agenda

https://avac.org/project/choice-agenda/

AVAC

https://avac.org/

PrEP4All

www.prep4all.org

www.prep4all.org/donate

Jeremiah Johnson: <u>Jeremiah@prep4all.org</u>
Michael Chancley: <u>Michael@prep4all.org</u>

Columbia Law School

https://www.law.columbia.edu/

Christopher Morten, JD, PhD: cjm2002@columbia.edu

PrEP4All 2019 Statement: Federal Government Sues Gilead for Patent Infringement on PrEP https://prep4all.org/the-federal-government-sues-gilead-for-patent-infringement-on-truvada-amp-descovy-prep/

PrEP4All 2022 Press Release: Advocates Demand Update on United States v. Gilead Sciences Lawsuit

https://prep4all.org/us-v-gilead-two-year-anniversary-prep4all-leads-25-advocacy-organizations-demanding-updates-on-hiv-prevention-drug-patent-lawsuit/

PrEP4All, the Public Interest Patent Law Institute, Columbia Law School and 32 organizations press DOJ to keep fighting 2023

https://prep4all.org/wp-content/uploads/2024/06/2023-05-30-Letter-of-P4A-PIPLI-to-DOJ-HHS.pdf

America's HIV Epidemic Analysis Dashboard

https://ahead.hiv.gov/?indicator=285&measure=count

Bloomberg Law: Gilead Win on US HIV-Drug Patents Survives, But New Risk Rises https://news.bloomberglaw.com/ip-law/gilead-win-on-us-hiv-drug-patents-survives-but-new-risk-rises

Health Affairs: Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously Estimated

https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2022.01134?journalCode=hlthaff

Johns Hopkins: New Policy Proposal Seeks to Improve Access to Medications that Prevent HIV Infection

https://publichealth.jhu.edu/departments/health-policy-and-management/research-and-practice/new-policy-proposal-seeks-to-improve-access-to-medications-that-prevent-hiv-infection#:~:text=Johns%20Hopkins%20faculty%20and%20colleagues,help%20end%20the%20HIV%20epidemic

Lancet: Equity of PrEP uptake by race, ethnicity, sex and region in the United States in the first decade of PrEP: a population-based analysis https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(24)00065-6/fulltext

LA Times: Column: Gilead says drug profits must stay high to pay for 'innovation,' but 100% of its profits went to shareholders

https://www.latimes.com/business/hiltzik/la-fi-hiltzik-gilead-profits-20171023-story.html

NBC News: 'This will shut us down': HIV prevention clinics brace for Gilead reimbursement cuts https://www.nbcnews.com/nbc-out/out-health-and-wellness/-will-shut-us-hiv-prevention-clinics-brace-gilead-reimbursement-cuts-rcna1346

NYT: Why Don't More Americans Use PrEP? https://www.nytimes.com/2018/07/16/opinion/prep-hiv-aids-drug.html

NYT: Who Owns H.I.V.-Prevention Drugs? The Taxpayers, U.S. Says https://www.nytimes.com/2019/11/08/health/hiv-prevention-truvada-patents.html

NYT: A Million Americans Need This Drug. Trump's Deal Won't Help Enough of Them https://www.nytimes.com/2019/05/13/opinion/truvada-gilead-hiv-trump.html

Out: Gilead May Owe \$1 Billion For Truvada Claim https://www.out.com/news/2019/8/19/gilead-may-owe-us-1-billion-truvada-claim

STAT: Biden administration appeals jury finding in battle over patents for HIV prevention pills https://www.statnews.com/pharmalot/2024/07/08/gilead-hiv-aids-truvada-descovy-patents-biden/

Washington Post: An HIV treatment cost taxpayers millions. The government patented it. But a

pharma giant is making billions

https://www.washingtonpost.com/business/economy/pharma-giant-profits-from-hiv-treatment-funded-by-taxpayers-and-patented-by-the-government/2019/03/26/cee5afb4-40fc-11e9-9361-301ffb5bd5e6_story.html

Washington Post: Gilead CEO insists federal government patent for HIV prevention pill Truvada is invalid

https://www.washingtonpost.com/business/economy/gilead-ceo-insists-federal-government-patent-for-hiv-prevention-pill-truvada-is-invalid/2019/05/16/7c0a79b6-77e1-11e9-b3f5-5673edf2d127_story.html